155 related articles for article (PubMed ID: 8571992)
1. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J
Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
5. Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.
van der Gaast A; Hulshof C; Kok TC; van Loon E; Splinter TA
Eur J Cancer; 1993; 29A(6):870-3. PubMed ID: 8484981
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Schwartz DC
Tumour Biol; 1991; 12(2):82-90. PubMed ID: 2028182
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
Nicolini A; Ferdeghini M; Colombini C; Carpi A
J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
[TBL] [Abstract][Full Text] [Related]
9. Serum CA-125 measurements > 65 U/mL. Clinical value.
Eltabbakh GH; Belinson JL; Kennedy AW; Gupta M; Webster K; Blumenson LE
J Reprod Med; 1997 Oct; 42(10):617-24. PubMed ID: 9350014
[TBL] [Abstract][Full Text] [Related]
10. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
Yedema CA; Kenemans P; Wobbes T; Thomas CM; Bon GG; Mulder C; Voorhorst FJ; Verstraeten AA; van Kamp GJ; Hilgers J
Tumour Biol; 1992; 13(1-2):18-26. PubMed ID: 1589694
[TBL] [Abstract][Full Text] [Related]
11. CA 549 as a marker in breast cancer.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.
Jezersek B; Cervek J; Rudolf Z; Novaković S
Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092
[TBL] [Abstract][Full Text] [Related]
13. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
14. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
Shabana A; Onsrud M
Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
[TBL] [Abstract][Full Text] [Related]
15. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
Yenisey C; Güner G
Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
[No Abstract] [Full Text] [Related]
16. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
17. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
18. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
Bon GG; Verheijen RH; Zuetenhorst JM; van Kamp GJ; Verstraeten AA; Kenemans P
Gynecol Obstet Invest; 1996; 42(1):58-62. PubMed ID: 8840180
[TBL] [Abstract][Full Text] [Related]
19. The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen.
Kopczyński Z; Thielemann A
Eur J Gynaecol Oncol; 1998; 19(5):503-7. PubMed ID: 9863926
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
